Cowen & Co. Believes Ultragenyx (RARE) Still Has Room to Grow


In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ultragenyx (NASDAQ: RARE). The company’s shares opened today at $84.43, close to its 52-week high of $87.33.

According to TipRanks.com, Baral is a top 100 analyst with an average return of 33.2% and a 57.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx with a $91.60 average price target, implying an 8.5% upside from current levels. In a report issued on August 20, SunTrust Robinson also maintained a Buy rating on the stock with a $83 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $87.33 and a one-year low of $41.67. Currently, Ultragenyx has an average volume of 482.2K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts